普萘洛尔在套扎方案中用于食管静脉曲张出血二级预防的随机对照试验
该随机对照试验比较了食管静脉曲张根除前联用普萘洛尔与长期联用普萘洛尔在二级预防食管静脉曲张出血中的再出血率。结果显示A组再出血率11.3% vs B组10.4%,差值0.9%(95%CI -7.5%至9.3%),非劣效性成立。
要点
- 套扎联合普萘洛尔至静脉曲张根除在再出血率上非劣于长期联用普萘洛尔。
- A组再出血11.3% vs B组10.4%,差值0.9%(95%CI -7.5%至9.3%)。
- 进一步失代偿和死亡率两组差异未达统计学显著,原文认为需进一步研究。
核心结论
- 套扎联合普萘洛尔至食管静脉曲张根除在食管静脉曲张出血二级预防中非劣于套扎联合继续普萘洛尔。
- 对进一步失代偿和无移植生存的影响值得进一步研究。
研究设计与样本
- 随机对照试验,纳入控制急性食管静脉曲张出血后的肝硬化患者,随机分为2组,每组106例。
- A组接受套扎联合普萘洛尔至食管静脉曲张根除,B组接受标准治疗继续普萘洛尔;两组随访内镜下均对复发性静脉曲张进行套扎。
- A组中位随访23.0个月(n=106),B组中位随访23.6个月(n=106)。
主要发现
- A组12例(11.3%)vs B组11例(10.4%)发生复发性食管静脉曲张出血,再出血率差值0.9%(95%CI -7.5%至9.3%)。
- 差值95%CI上限在13.2%界值内,A组对B组的非劣效性成立。
- A组38例(35.8%)vs B组40例(37.7%)出现进一步失代偿,差值-1.9%(95%CI -14.9%至11.1%)。
- A组24例(22.6%)vs B组26例(24.5%)死亡,死亡率差值-1.9%(95%CI -13.3%至9.5%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Endoscopic variceal ligation (EVL) plus nonselective β-blockers (NSBB) is the standard of care for secondary prophylaxis of esophageal variceal bleeding (EVB). This trial aimed to compare the rebleeding rates between EVL plus NSBB till eradication of esophageal varices (EEV) and EVL plus long-term NSBB. METHODS: After control of acute EVB, patients with cirrhosis were randomized into 2 groups, with group A patients receiving EVL plus propranolol till EEV, while group B patients received standard of care with continuation of propranolol. Recurrent varices were ligated at follow-up endoscopy in both groups. RESULTS: The median follow-up period was 23.0 months in group A (n = 106) and 23.6 months in group B (n = 106). Twelve patients (11.3%) in group A and 11 (10.4%) in group B had recurrent EVB. The difference in rebleeding rates and the 95% confidence interval (CI) was 0.9% (-7.5% to 9.3%). The upper 95% CI bound of the difference was within the margin of 13.2%, and the noninferiority of group A to group B was established. Thirty-eight patients (35.8%) in group A and 40 (37.7%) in group B had further decompensation, with the difference (95% CI) of -1.9% (-14.9% to 11.1%). Twenty-four patients (22.6%) in group A and 26 (24.5%) in group B expired, with the difference (95% CI) in mortality rates of -1.9% (-13.3% to 9.5%). DISCUSSION: EVL plus propranolol till EEV was noninferior to EVL plus continuing propranolol in secondary prophylaxis of EVB, but the impact on further decompensation and transplantation-free survival deserved further investigation.
引用
- Chen WC, Yang TC, Lee PC, et al. A Randomized Controlled Trial of Propranolol Use During Ligation Program for Secondary Prophylaxis of Esophageal Variceal Bleeding. Am J Gastroenterol. 2023. PMID: 37543755. doi:10.14309/ajg.0000000000002457
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。